Home » EMEA Completes the Review of Recombinant Factor VIII Products and Inhibitor Development
EMEA Completes the Review of Recombinant Factor VIII Products and Inhibitor Development
The European Medicines Agency (EMEA) has completed a review of data on recombinant factor VIII (FVIII) products and the risk of the development of inhibitors against these products.
EMEA
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May